Previous 10 | Next 10 |
2023-11-16 05:28:02 ET Related stories Palo Alto Networks Q1'FY24 Review: Billings Weakness Creates Buying Opportunity Palo Alto Networks, Inc. (PANW) Q1 2024 Earnings Call Transcript Maxeon Solar Technologies Ltd (MAXN) Q3 2023 Earnings Call Transcript Cisco...
- First regulatory authorization of a CRISPR-based gene-editing therapy in the world – - CASGEVY is indicated for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises who have the βS/βS, βS/β+ or...
2023-11-14 05:00:00 ET The S&P 500 posted its best week of the year earlier this month, gaining more than 5%, and the index extended the gain last week with an increase of more than 1%. It's impossible to predict whether the rally will last and lead to a bull market -- or if we'll h...
2023-11-12 08:18:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to biotech stocks , I usually like to take a “Goldilocks” approach. This involves investing in biotech companies that have one or more promising drugs in mid-to-...
2023-11-11 08:30:00 ET Investing in healthcare stocks has its perks. Since medical services are always in high demand, investors can rest assured that the industry won't stop being relevant anytime soon. Still, things evolve quickly in healthcare, so it's important to find stocks that c...
2023-11-10 16:50:48 ET Summary Beam Therapeutics Inc.'s valuation has declined, as its progress in identifying candidates to work with its base editing technology and moving them into the clinic has been slow. Beam's lead program for Sickle Cell Disease is way behind CRISPR Therap...
2023-11-08 10:07:00 ET CRISPR Therapeutics (NASDAQ: CRSP) is a company that doesn't have an approved product on the market. Its operations are unprofitable, and it is burning through cash. There are many reasons that this may look like a risky, dangerous stock to own. But there's a ...
2023-11-07 18:52:31 ET Leading gene therapy company CRISPR Therapeutics (NASDAQ: CRSP) had quite the memorable day on the market Tuesday. Following the release of encouraging quarterly results, bulls ran rampant on the stock, and it closed almost 14% higher. Meanwhile, the bellwethe...
2023-11-07 07:20:51 ET More on CRISPR Therapeutics CRISPR Therapeutics: Positive Exa-Cel AdCom Opens Door For Historic Approval Risk And Reward: Evaluating Crispr's Exa-Cel For Sickle Cell Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A B...
CRISPR Therapeutics AG (CRSP) is expected to report $-1.98 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
CRISPR Therapeutics AG Company Name:
CRSP Stock Symbol:
NASDAQ Market:
CRISPR Therapeutics AG Website:
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...